EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR ‐ TKI Treatment: A Retrospective Cohort Study

Yi-Tse Su iD, Shu-Farn Tey, Chung-Ta Lee, Chien-Yu Lin, Jeng-Shiuan Tsai, Chien-Chung Lin, Chin-Wei Kuo

The Kaohsiung Journal of Medical Sciences · 2025

DOI: 10.1002/kjm2.70023 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2025. Verfasst von Yi-Tse Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung Univer…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Angiogenesis Inhibitors, Immunotherapy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced‐stage EGFR‐mutated lung non‐small cell lung cancer (NSCLC) challenges current treatment paradigms, particularly after frontline EGFR‐TKI therapy failure. This study investigates the survival impact of combined anti‐angiogenic agent and immunochemotherapy (AICT) for this population. We retrospectively analyzed NSCLC patients at National Cheng Kung University Hospital from January 2010 to December 2022, focusing on those who had disease progression beyond frontline EGFR‐TKI treatments. Survival outcomes were assessed through progression‐free survival (PFS) and overall survival post‐TKI failure (OSpTKI). Propensity score was employed to match patients, with Kaplan–Meier curve and multivariable Cox regression analysis determining the survival benefits. Analyses were also performed for subgroups based on PD‐L1 level, treatment lines, and regimens. A total of 412 patients were enrolled, with 27 receiving AICT. Compared to patients who did not receive AICT, those who received AICT had longer PFS (5.9 vs. 3.9 months, p = 0.024) and longer OSpTKI (17.9 vs. 11.9 months, p = 0.018). The observed survival advantage in PFS and OSpTKI was consistent in both the original cohort (for PFS: hazard ratio [HR] = 0.59, 95% confidence interval [CI] = 0.39–0.90, p = 0.014; for OSpTKI: HR = 0.41, 95% CI = 0.24–0.69, p < 0.001) and after propensity score matching (for PFS: HR = 0.56, 95% CI = 0.35–0.98, p = 0.014; for OSpTKI: HR = 0.45, 95% CI = 0.26–0.79, p = 0.006). In the subgroup analyses, patients with PD‐L1 ≥ 1%, those who received AICT as a second‐line therapy, or those treated in conjunction with pemetrexed showed a PFS benefit. AICT improves survival outcomes in advanced‐stage EGFR‐mutated NSCLC, advocating for its integration into treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAngiogenesis InhibitorsImmunotherapyProtein Kinase InhibitorsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedErbB ReceptorsSurvival AnalysisProgression-Free SurvivalB7-H1 AntigenAdult

Stichwörter der Autor:innen

EGFR mutationNSCLCanti‐angiogenic agentimmunotherapysurvival

Substanzen

ErbB ReceptorsAngiogenesis InhibitorsEGFR protein, humanProtein Kinase InhibitorsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Division of Pulmonary Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
  • School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Department of Pathology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

ORCID-Profile: Yi-Tse Su

Förderung

  • National Science and Technology Council

Zitieren

APA

Su, Y. T., Tey, S. F., Lee, C. T., Lin, C. Y., Tsai, J. S., Lin, C. C., & Kuo, C. W. (2025). Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR ‐ TKI Treatment: A Retrospective Cohort Study. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70023

Vancouver

Su YT, Tey SF, Lee CT, Lin CY, Tsai JS, Lin CC, et al. Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR ‐ TKI Treatment: A Retrospective Cohort Study. The Kaohsiung Journal of Medical Sciences. 2025. doi:10.1002/kjm2.70023

BibTeX
@article{Su2025,
  author = {Su, Yi-Tse and Tey, Shu-Farn and Lee, Chung-Ta and Lin, Chien-Yu and Tsai, Jeng-Shiuan and Lin, Chien-Chung and Kuo, Chin-Wei},
  title = {Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR ‐ TKI Treatment: A Retrospective Cohort Study},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2025},
  doi = {10.1002/kjm2.70023}
}
Kostenlos starten →